Edesa Biotech Terminates Material Agreement

TL;DR

Edesa Biotech just terminated a big deal, filing an 8-K today.

AI Summary

Edesa Biotech, Inc. announced on October 3, 2024, the termination of a material definitive agreement. The company also filed financial statements and exhibits as part of this 8-K report.

Why It Matters

The termination of a material definitive agreement can significantly impact a company's strategic direction and financial outlook.

Risk Assessment

Risk Level: medium — Termination of a material agreement introduces uncertainty regarding the company's future operations and financial stability.

Key Players & Entities

• Edesa Biotech, Inc. (company) — Registrant
• October 3, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $3,870,000 — ATM Prospectus Supplement is currently $3,870,000, which is based on the limitations of G
• $50,000 — he Agreement in an amount not to exceed $50,000 in the aggregate, in addition to $2,500
• $2,500 — 50,000 in the aggregate, in addition to $2,500 per due diligence session update for Wa
• $8.37 million — ng an aggregate offering price of up to $8.37 million from time to time through Canaccord. Th
• $2.0 million — Agreement for proceeds of approximately $2.0 million from March 27, 2023 through the date of

Filing Documents

• f8k_100424.htm (8-K) — 27KB
• exh_11.htm (EX-1.1) — 216KB
• exh_51.htm (EX-5.1) — 14KB
• faskenheader.jpg (GRAPHIC) — 19KB
• faskenfooter.jpg (GRAPHIC) — 1KB
• faskenlogo.jpg (GRAPHIC) — 3KB
• 0001171843-24-005515.txt ( ) — 517KB
• edsa-20241003_lab.xml (EX-101.LAB) — 33KB
• edsa-20241003_pre.xml (EX-101.PRE) — 22KB
• edsa-20241003.xsd (EX-101.SCH) — 3KB
• f8k_100424_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. On October 4, 2024, Edesa Biotech, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Agreement") with H.C. Wainwright & Co., LLC, as sales agent ("Wainwright"), to sell its common shares, without par value (the "Shares"), from time to time, in an "at the market offering" program through Wainwright, with certain limitations on the amount of Shares that may be offered and sold thereunder. The sales, if any, of the Shares made under the Agreement will be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the "Securities Act") including sales made directly on or through the Nasdaq Capital Market or on any other existing trading market for the Company's common shares, directly to Wainwright as principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, and/or in any other method permitted by law. The Shares, if any, will be issued pursuant to a prospectus supplement, dated October 4, 2024, and an accompanying base prospectus, dated August 12, 2022, contained therein (the "ATM Prospectus Supplement"), which together form a part of the Company's "shelf" registration statement on Form S-3 (File No. 333-266604) filed by the Company with the Securities and Exchange Commission ("SEC") on August 5, 2022 and declared effective by the SEC on August 12, 2022. The aggregate market value of the Shares eligible for sale under the ATM Prospectus Supplement is currently $3,870,000, which is based on the limitations of General Instruction I.B.6 of Form S-3. The Company will pay Wainwright a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and has agreed to provide Wainwright with customary indemnification and contribution rights, including for liabilities under the Securities Act.

02

Item 1.02. Termination of Material Definitive Agreement. On October 3, 2024, the Company terminated its Equity Distribution Agreement (the "Distribution Agreement"), dated March 27, 2023, with Canaccord Genuity LLC ("Canaccord"). The termination of the Distribution Agreement was effective as of October 3, 2024. As previously reported, pursuant to the terms of the Distribution Agreement, the Company could offer and sell its common shares having an aggregate offering price of up to $8.37 million from time to time through Canaccord. The Company is not subject to any termination penalties related to the termination of the Distribution Agreement. The Company sold a total of 368,309 common shares pursuant to the Distribution Agreement for proceeds of approximately $2.0 million from March 27, 2023 through the date of termination of the Distribution Agreement.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 At The Market Offering Agreement, dated October 4, 2024, by and between Edesa Biotech, Inc. and H.C. Wainwright & Co., LLC 5.1 Opinion of Fasken Martineau DuMoulin LLP regarding legality of the Shares. 23.1 Consent of Fasken Martineau DuMoulin LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Edesa Biotech, Inc. Date: October 4, 2024 By: / s/ Stephen Lemieux Name: Stephen Lemieux Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR